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ABSTRACT
Contrary to conventional cancer therapies, immunotherapy manipulates an individual’s body cells to fight cancer, 
enhancing the active and dynamic immune interactions between the tumour and host. Cancer immunotherapy provides 
evidence of success through a variety of treatment approaches.  Utilizing T-cells and antibodies, immunotherapy 
strategies such as T-cell engaging bodies, checkpoint inhibitors and engineered T-cells have significantly increased 
the chance of survival for many cancer patients. The combinations of these immunotherapies have also granted 
greater success in the elimination of tumour cells. Immunotherapy breakthroughs have the potential to have a 
lasting impact on cancer treatment. This literature review sheds light on the importance in further research for cancer 
immunotherapy and a glimpse at all of its powerful results.
Contrairement aux méthodes conventionnelles de traitement anti-cancereux, l’immunothérapie manipule les cellules 
somatiques d’un patient pour battre contre le cancer, améliorant les interactions immunitaires actives et dynamiques 
entre la tumeur et l’hôte. Par une variété de méthodes de traitement, il y a une abondance de preuve qui montre le 
succès exceptionnel dans l’utilisation de l’immunothérapie contre le cancer. Les stratégies immunothérapeutiques, 
par exemple l’utilisation des anticorps bispécifiques qui engagent les cellules T, des inhibiteurs de checkpoint et les 
cellules T ingénierées, ont augmenté considérablement la chance de survie pour beaucoup de patients frappés 
par le cancer. Les combinaisons de ces immunothérapies ont aussi permis des grands succès avec l’élimination 
des cellules cancéreux. L’immunothérapie a mené à des nombreuses percées qui vont avoir un impact durable 
sur le traitement de cancer. Elle fournit continuellement des nouvelles découvertes qui ont déjà commencées de 
révolutionner les thérapies de cancer. Cette revue littéraire éclaircit l’importance de la continuation des recherches 




Cancer immunotherapy began in the 1890s, when Dr. 
William Coley proved that he could treat advanced 
cancers with tuberculosis vaccine injections inducing 
tumour regressions in some patients (Parish, 
2003; Hoption Cann et al., 2003). Some significant 
responses were recorded over the ensuing forty years, 
but successes were sporadic, difficult to reproduce 
and were not obtained in a scientifically rigorous 
fashion (Hoption Cann et al., 2003). Coley’s strategy 
was further discounted due to the risks associated 
with the administration of infectious agents to already 
weakened cancer patients (Mellman et al., 2011). 
Thus, the success of immunotherapy seemed unlikely, 
slowing the development of immunotherapeutic 
progress in cancer for many decades (Biemar et al., 
2013).
The immune system and tumor cells have a dynamic 
relationship where the immune system is seeking 
to eliminate tumour cells, whereas tumour cells are 
seeking to evade the immune system (Yokota, 2000). 
In cancer, tumour cells use many evasive techniques 
to avoid the immune system such as T-cell anergy, 
dendritic cell defects, secretion of immunosuppressive 
cytokines, resistance to apoptosis, and deficient 
expression of immunomodulatory molecules (Seliger, 
2005). Cancer is treated by reducing or removing 
tumours as well as avoiding tumour development 
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through common methods such as surgery, radiation 
therapy, chemotherapy, and external drug use (Rees, 
2014). However, these methods come along with 
adverse side effects that critically impact one’s health 
(Canadian Cancer Society, 2016). Fortunately, these 
treatments can be replaced with the best natural 
defense mechanism of all – the immune system.
Cancer immunotherapy encompasses treatments 
that are meant to strengthen immune responses 
against tumours so that cancerous cells can be more 
effectively eliminated (Janeway, 2005). The immune 
system has not been able to effectively recognize 
and attack cancer since cancer cells can be altered 
and grow out of control (American Society of Clinical 
Oncology, 2016). The body normally kills cancer cells 
or abnormally growing cells, however, these cells 
can often evade detection by immune cells when 
reducing tumour antigen cell surface expression 
(American Society of Clinical Oncology, 2016). Cancer 
immunosurveillance is demonstrated when molecules 
on the surface of cancer cells, known as tumour-
associated antigens (TAAs) are detected by the 
immune system (Remedios, 1980). The identification 
of tumour markers in TAAs provides targets for 
attacking the cancer (Remedios, 1980). Innate 
and adaptive immunity are both critical responses 
to the immune system (The University of Arizona, 
2000). Adaptive immunity confers antigen specific 
immune responses, while innate immunity refers to 
nonspecific defence mechanisms (The University of 
Arizona, 2000). Cancer immunotherapies rely heavily 
on the adaptive immune response more because it 
includes a “memory” that makes future responses 
against a specific antigen more efficient (OpenStax, 
2016). Memory T-cells and B-cells are immune cells 
that remain in the body and retain a memory of a 
pathogen. If a pathogen is re-encountered, memory 
T and B-cells can immediately trigger a fast and 
powerful immune response (OpenStax, 2016). The 
memory-based advantage associated with cancer 
immunotherapy significantly helps the long term care 
of patients as immunologic memory provides the 
host with long-lived protection from future pathogen 
encounters (American Society of Clinical Oncology, 
2016; Klebanoff et al., 2006).
There are two types of immune cells that are important 
to the success of these therapies, T-cells and B-cells. 
T-cells are immune cells that recognize antigen 
fragments presented at cell surfaces by specialized 
antibody-like receptors (Janeway, 2005). They work 
to attack cells carrying certain foreign or abnormal 
fragments (Janeway, 2005). In addition, B-cells are 
another type of immune cell that plays a key role in 
activating T-cells (Janeway, 2005). Each B-cell is 
programmed to make one specific antibody, and when 
a B-cell encounters its triggering antigen, it activates 
and differentiates into plasma cells (Janeway, 2005). 
The plasma cells then manufacture millions of 
identical antibody molecules that bind the antigens to 
mark the cells for destruction (Janeway, 2005). Helper 
T-cells as well have a critical role in helping B-cells 
by stimulating nearby B-cells to produce antibodies 
(Janeway, 2005).
Cancer immunotherapy dramatically alters the 
immune-cancer relationship to allow for disease 
control up to complete remission. Immunotherapy 
offers several advantages to today’s standard 
treatments from its unique approach to arming the 
body’s own immune system with numerous molecular 
weapons instead of directing a therapy against a 
single tumour target (National Cancer Institute, 2016). 
Activated and tumour-specific immune cells can reach 
areas that a surgeon cannot, and when the immune 
system is appropriately stimulated, it can target even 
microscopic diseases and disseminated metastases 
(Dimberu et al., 2011). Furthermore, immunotherapy 
avoids the adverse side effects by only attacking 
the tumour cells, and avoiding the target of healthy 
cells that chemotherapy and radiation therapy can 
strike on (Dimberu et al., 2011). Successful trials and 
experiments have been accomplished with effective 
results using methods such as T-cell engaging bodies, 
checkpoint inhibitors and engineered T-cells (Huehls 
et al., 2014; Alberts et al., 2002; Levine, 2015).
Cancer immunotherapy is an emerging field that 
is only beginning to show its potential. A revolution 
of pharmaceutical, academic, and investor interest 
should ready us for the hope of an exquisitely 
effective cancer therapy with the adverse side 
effects present in chemotherapy to be obsolete. 
This paper encompasses the main methods of 
cancer immunotherapy treatment and its successful 
results based on the molecular pathways targeted 
and techniques used that ultimately triumph cancer 
immunotherapy’s astounding potential for the future
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CURRENT CANCER IMMUNOTHERAPY 
METHODS
T-Cell Engaging Bodies
Bispecific T-cell engagers (BiTEs) are molecules that 
enhance the patient’s immune response to tumours 
by retargeting T-cells to tumour cells (Huehls et al., 
2014). A BiTE is constructed of two single-chain 
variable fragments (scFv) connected in tandem by 
a flexible linker. One scFv binds to a T-cell-specific 
molecule, usually the protein complex CD3, whereas 
the second scFv binds to a tumour-associated antigen 
(Huehls et al., 2014). These T-cell engaging molecules 
stimulate the immune system by bringing the tumour 
cell in close proximity to T-cells activated through their 
cell membrane receptors (Huehls et al., 2014). T-cells 
expand rapidly upon activation producing durable 
cytotoxic responses with the potential to generate 
immunologic memory by continually executing the 
immune response and increasing the likelihood of 
the eradication in cancer cells (Huehls et al., 2014). 
T-cells have been found to attack tumours from the 
outside and as well as infiltrate into the tumour. These 
features make T-cells optimal therapeutic effectors 
for cancer as specificity allows a BiTE to bridge a 
T-cell with a tumour cell, stimulating T-cell activation, 
tumour cell lysis and cytokine production (Huehls et 
al., 2014). The efficiency and exceptional potency 
of BiTEs for therapeutics have been demonstrated 
multiple times in both animal models and humans 
(Huehls et al., 2014). In animals, mouse models have 
shown that microgram doses of this agent are able to 
promote tumour regression of colorectal and ovarian 
cancer (Huehls et al., 2014). In humans, BiTEs have 
shown complete and partial responses in a phase I 
trial of the BiTE blinatumomab at small doses in non-
Hodgkin B-cell lymphoma patients (Huehls et al., 
2014).
Checkpoint Inhibitors
T-cell activation is tightly regulated in order to maintain 
self-tolerance for minimal collateral damage in 
peripheral tissues. With checkpoint inhibitors, the tight 
regulation system that dampens down the immune 
response is impaired, removing immune-checkpoint 
blockades for a stronger physiological immune 
response (Alberts et al., 2002). This is exploited 
as a method of cancer treatment that intensifies 
the activation of T-cells (Alberts et al., 2002). T-cell 
activation begins when antigens are presented during 
the engagement of the T-cell receptor (TCR) and 
peptide from the major histocompatibility complex 
to the T-cell (Alberts et al., 2002). Afterwards, co-
stimulation occurs when T-cells receive signals 
usually from B7 proteins such as CD80 and CD86 
(Pardoll, 2012).
CTLA-4 (Cytotoxic T-lymphocyte Associated Protein 
4) and PD-1 (Programmed Cell Death Protein 1) are 
both inhibitory receptors that suppress and down 
regulate the T-cell effector function (Bristol-Myers 
Squibb Canada, 2016). CTLA-4 primarily counteracts 
the activity of the T-cell co-stimulatory receptor CD28 
that is essential to amplify TCR signaling when 
activating T-cells (Bristol-Myers Squibb Canada, 
2016). CTLA-4 down-modulates CD4+, harming 
T-cell activity since it enhances regulatory T-cells 
that are responsible for immunosuppressive activity 
(Bristol-Myers Squibb Canada, 2016). The major 
role of the inhibitory receptor PD-1 also limits the 
activity of T-cells in peripheral tissues during an 
inflammatory response to infection (Bristol-Myers 
Squibb Canada, 2016). PD-1 limits the activity and 
autoimmunity of T-cells in peripheral tissues during 
infection (Bristol-Myers Squibb Canada, 2016) (Fig 
1). Removing CTLA-4 and PD-1 interactions with 
their receptors using an inhibitor, strengthens T-cell 
activation and downstream effector responses (Hodi 
et al., 2010). In 2012, Health Canada approved the 
antibody ipilimumab, which targets the blockade 
molecule CTLA-4 (Hodi et al., 2010). Patients with 
terminal melanoma showed an outstanding 20% 
response rate when treated with ipilimumab (Awad 
et al., 2015). In a phase 3 study of ipilimumab, the 
overall survival was 10 months among patients taking 
the therapy as compared to the previous expectancy 
of 6.4 months (Awad et al., 2015). Additionally, 18% 
of the ipilimumab-treated patients survived beyond 
two years, a remarkable improvement from the 5% 
with previous medicinal treatments (Brower, 2016). 
The impressive survival benefits stay consistent with 
drugs that block PD-1 action. Disruption of PD-1 
pathway signaling represents a major breakthrough 
in treatment of tumour types like melanoma, lung 
cancer, bladder cancer, and Hodgkin’s lymphoma 
(Brower, 2016). Compared to chemotherapy, which 
has a response rate less than 10% with a one year 
survival rate of 30%, Gettinger et al. showed that PD-1 
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inhibition had a response rate of 17% and an 18% 
three year survival rate (Brower, 2016). Over half of 
the patients in the trial had received more than three 
lines of systematic therapy beforehand, therefore 
providing exceeding results from such a heavily 
pre-medicated group (Brower, 2016). These studies 
show that immunotherapy can be a significantly more 
effective form of cancer treatment than traditional 
chemotherapy.
Engineered T-Cells
Engineered T-cells with synthetic receptors known 
as chimeric antigen receptors (CARs) have also 
been proven effective in eliminating tumour cells 
(Wolchok et al., 2014). The process of engineered 
T-cells begins by separating white blood cells from 
the blood, extracting T-cells, and returning red cells 
and platelets to the patient (Jarvis, 2014). A viral 
vector inserts into T-cells with genes carrying the 
instructions for a CAR that tethers the antibody to 
promote co-stimulatory signals to divide the cell. A 
bioreactor is used to increase the amount of T-cells 
with the help of magnetic beads coated with two 
antibodies, anti-CD3 and anti-CD28, that signal the 
T-cells to proliferate (Levine, 2015). The patient is 
then given chemotherapy to lower their white blood 
cell count, increasing the immune system’s chances 
of accepting the reprogrammed T-cells (Levine, 
2015). The patient’s blood is then infused back with 
the reprogrammed T-cells that will destroy cancer 
cells expressing the antigen targeted by the CAR 
(Levine, 2015). The customization of T-cells available 
to the patient’s specific form of cancer is a unique 
benefit of engineered T-cells. The modifications in 
T-cells promote convenience and efficiency in the 
particular treatment exploited. 
The reduction of tumour growth is incredibly effective 
through CARs, but despite promising clinical results, 
there are critical concerns for engineered T-cells as 
their excessive activity can make them difficult to 
control (Wu et al., 2015). This can result in adverse side 
effects, including life threatening inflammatory risks 
for severe toxicity from their potent immune activity 
(Wu et al., 2015). However, a study by Lin and Onuffer 
has found a way to control the activity by developing 
a CAR that is switched on only in the presence of 
both of its cognate antigen and a small-molecule drug 
(Bird, 2015). Previously with conventional CARs, the 
cognate antigen is usually activated upon binding 
from the TCR and co-stimulatory molecules (Bird, 
2015). Although, for better regulation of this activity, 
the new design has different constructs in which 
the extracellular antigen-binding and intracellular 
signaling components were split in the presence 
of a small molecule referred to as a rapalog (Bird, 
2015). The on-switch CAR exemplifies a simple and 
effective strategy, diminishing unwanted side effects 
and allowing precise control over the amount, timing 
and location of CAR T-cell activities.
Combination of Immunotherapy Treatment
Preclinical models have proven the importance of a 
complex integrated immune response in eliminating 
tumours (Vanneman et al., 2011). Combinations 
of immunotherapies are anticipated to be far more 
effective than monotherapies (Vanneman et al., 
2011).  Various integrations of cancer immunotherapy 
treatments suggest intriguing potential in what lies 
ahead for therapeutic synergy with complementary 
modes of action targeting cancer cells (Pardoll et al., 
2012). Preclinical models have validated dramatic 
synergy between tumour vaccines and inhibition of 
most of the immune checkpoints (Pardoll et al., 2012). 
Anti-CTLA-4 therapy strongly enhances the amplitude 
of vaccine-induced anti-tumour responses in many 
poorly immunogenic tumour models, as does anti-
PD1 therapy (Pardoll et al., 2012). BiTEs may also be 
significantly more effective in combination with other 
therapies. In particular, their association with immune 
checkpoint inhibitors, such as CTLA-4 and PD-1 
inhibitors, allows for greater T-cell activation (Hodi et 
al., 2010). For melanoma patients, a staggering 65% 
of patients treated with a combination of blocking both 
CTLA-4 and PD-1 had their tumours stop growing 
(Hodi et al., 2010). These results prove to be very 
promising, showing the great potency achievable by 
combinatorial strategies.
DISCUSSION
Ethical Implications of Access to New Therapies and 
Costs
Immunotherapy has proven to be a stronger approach 
to fighting cancer cells when compared to traditional 
chemotherapy. Chemotherapy is a popular method 
for cancer treatment using chemical based drugs 
to treat cancer (National Center for Biotechnology 
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Information, 2016). It is an effective approach that 
targets cancer cells, but also attacks healthy, fast 
dividing cells, causing unpleasant side effects for the 
patient (National Center for Biotechnology Information, 
2016). To begin with, a very short ten-minute drip using 
immunotherapy can effectively treat leukemia, while 
current chemotherapy treatments for leukemia can 
last for over a year (MIT Technology Review, 2016). 
Chemotherapy is endured over a longer period of time 
since treatment is given in cycles for the cancer cells 
to be attacked at their most vulnerable times, and to 
give normal cells time to recover from the damage 
(Chemocare, 2016). Treatment sessions can last 
up to four hours and more time may be needed for 
treating side effects. Not only does chemotherapy 
concern time, but also evokes permanent damage 
attacking healthy cells formed in the bone marrow, 
digestive tract, reproductive system, and hair follicles, 
while immunotherapy conveniently avoids all of 
these chronic side effects (Themeli et al., 2013). 
Furthermore, the hospital bills for leukemia patients 
can reach up to two million dollars, which is four times 
the cost of immunotherapy (MIT Technology Review, 
2016).
Others misleadingly advocate cancer immunotherapy 
to be corrupt because of the controversial high 
financial costs of treatments that have been 
constantly disputed. Cost is a remarkable obstacle 
against immunotherapy. The price of one treatment 
is half a million dollars (MIT Technology Review, 
2016). It is only available to those are more affluent, 
and not an option for the majority of the population. 
This is incredibly unfortunate; the help is available 
yet the accessibility is not. It is understandable that 
there is a high asking price relative to the expenses 
of health care and the lasting value of the treatment. 
It is inevitable for the treatment to be costly when 
immense efforts are continuously put into research 
involving highly educated professionals, high quality 
equipment, and complex analyses of data. However, 
the government needs to consider making it more 
widely available as the treatment has been shown to 
work successfully for various types of cancers. Cancer 
immunotherapy may have high initial costs, but it 
provides powerful, and long lasting results. The likely 
improvements in mass production of immunotherapy 
treatment will also be able to decrease the costs. The 
rising possibility of T-cell mass production continues 
with optimizing growth of T-cells in the lab, using 
electricity or pressure to introduce genetic material 
into cells, and the continued success of therapies in 
mouse cancer models (Topalian et al., 2011).
CONCLUSION
The remarkable effects seen in T-cell engaging bodies, 
checkpoint inhibitors and engineered T-cells are only 
the beginning of cancer immunotherapy. There are 
still numerous more immunotherapeutic methods and 
findings to be discovered to advance the future of 
cancer immunotherapy. In the past, immunotherapy 
was not respected as a field because of the lack of 
demonstrated clinical benefits and adverse effects. 
Today, some still believe immunotherapy to be 
ineffective. Although there was initial skepticism 
towards this field because of the many failed attempts 
in the earlier decades, there is still a need to start 
paying attention to the powerful results seen in current 
clinical trials rather than stay put with the past mindset 
of immunotherapy. A paradigm shift has already shown 
clear clinical benefits, therefore, it is counterintuitive 
to stick to the standards developed a generation ago. 
Proper research funding for cancer immunotherapy 
is needed, especially with its impressive impacts. 
It has the potential to replace traditional treatments 
with new molecular pathways and techniques that 
have been proven to be more effective. With cancer 
immunotherapy comes the beginning of revolutionizing 
cancer therapeutics, leading to an incredible future in 
the fight against cancer.
ABBREVIATIONS
TAA Tumour-Associated Antigen
BiTES Bispecific T-cell engagers
CD3 Cluster of differentiation 3
scFv  Single-chain variable fragments
TCR T-Cell Receptor
CTLA-4 Cytotoxic T-lymphocyte   
Associated Protein 4
PD-1 Programmed Cell Death Protein 1
CAR  Chimeric antigen receptor
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